Core Insights - Revvity Inc. shares declined over 2% despite exceeding third-quarter adjusted earnings expectations and raising the full-year profit outlook [1] Financial Performance - The company reported adjusted earnings of $1.18 per share, surpassing the analyst consensus of $1.14 [2] - Revenue for the quarter was $699 million, aligning closely with expectations of $699.39 million, and reflecting a 2% increase from the prior-year quarter [2] - Organic revenue growth was reported at 1% year-over-year [2] Segment Performance - The Diagnostics division experienced a 3% rise in revenue, totaling $356 million [3] - The Life Sciences segment saw a 1% increase in revenue, reaching $343 million [3] - Both segments reported year-over-year declines in adjusted operating margins [3] Future Outlook - Revvity updated its 2025 revenue forecast to a range of $2.83 billion to $2.88 billion, accounting for foreign exchange adjustments [4] - The company maintained its organic growth outlook of 2–4% [4] - Adjusted earnings guidance was raised to $4.90–$5.00 per share, exceeding the consensus estimate of $4.87 [4]

Core Insights - Revvity, Inc. is a leading provider of health science solutions with a market cap of $10.6 billion, serving healthcare, academia, and government sectors with over 11,000 employees [1] Financial Performance - Revvity is expected to report adjusted earnings of $1.14 per share for Q3, a decrease of 10.9% from $1.28 in the same quarter last year [2] - For the full fiscal year 2025, adjusted EPS is projected to be $4.87, slightly down from $4.90 in 2024, with a forecasted increase to $5.35 in fiscal 2026, representing a 9.9% year-over-year growth [3] Stock Performance - RVTY stock has declined by 25.9% over the past 52 weeks, underperforming the Healthcare Select Sector SPDR Fund's 6.7% decline and the S&P 500 Index's 14.7% gain during the same period [4] - Following the release of better-than-expected Q2 results, Revvity's stock fell by 8.3%, despite a 4.1% year-over-year revenue growth to $720.3 million, which exceeded expectations [5] Guidance and Outlook - The company anticipates continued pressure on its margins and subdued organic revenue growth, leading to a reduction in its full-year organic revenue growth guidance from 3%-5% to 2%-4% [6] - Adjusted EPS guidance has also been lowered from $4.90-$5.00 to $4.85-$4.95, which has affected investor confidence [6]